It is possible that the main title of the report HTLV Type I and Type II is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
- HTLV-I associated myelopathy
- acute T-cell leukemia
- acute T-cell lymphoma
- tropical spastic paraparesis
HTLV-I was first isolated in 1980 from a patient originally thought to have a cutaneous lymphoma. It became clear that it was a distinct form of lymphoma, which was designated as acute T-cell leukemia/ lymphoma (ATL). Some years later, different groups in Martinique and Japan described an association between a chronic disease of the spinal cord and HTLV-I infection, which was later named HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Since then, several other conditions have been linked to HTLV infection.
It is estimated that between 10 and 20 million people are infected by HTLV-I in the world. Only 0.25-2% of the infected individuals will develop a progressive neurologic disease named HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Approximately 2-5% of HTLV-I carriers will develop ATL. More rarely, HTLV-I may lead to arthropathy, uveitis (inflammation of the eye), pneumonitis and thyroid problems. Areas of the world that are endemic to the HTLV-1 virus are the Caribbean, southern Japan, equatorial Africa, Middle East, South America, and Melanesia.
WE MOVE (Worldwide Education and Awareness for Movement Disorders)
5731 Mosholu Avenue
Bronx, NY 10471
Transverse Myelitis Association
1787 Sutter Parkway
Powell, OH 43065-8806
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126